Metraipolis › archive › dc_3740d60ec828

Low-dose theophylline in addition to ICS therapy in COPD patients: A systematic review and meta-analysis — Europe PMC PMID:34029327

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/34029327
DOI
10.1371/journal.pone.0251348
License (as archived)
CC0-1.0
Archived
2026-11-04T08:30:47.827Z
SHA-256 of the archived text
15164cc9ab91b5df1d7a80c46a3ad2844432945cc7856b919792b72cd7139f13
Stable URL of this page
https://metraipolis.com/documento/dc_3740d60ec828

How to cite

Low-dose theophylline in addition to ICS therapy in COPD patients: A systematic review and meta-analysis — Europe PMC PMID:34029327 — Europe PMC (en), https://europepmc.org/article/MED/34029327 (CC0-1.0); archived copy: https://metraipolis.com/documento/dc_3740d60ec828 (Metraipolis archive dc_3740d60ec828, sha256 15164cc9ab91b5df1d7a80c46a3ad2844432945cc7856b919792b72cd7139f13)
BibTeX
@misc{dc3740d60ec828,
  title = {Low-dose theophylline in addition to ICS therapy in COPD patients: A systematic review and meta-analysis — Europe PMC PMID:34029327},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/34029327},
  note = {License CC0-1.0; archived copy https://metraipolis.com/documento/dc_3740d60ec828; sha256 15164cc9ab91b5df1d7a80c46a3ad2844432945cc7856b919792b72cd7139f13},
  year = {2026}
}

Archived text

Reproduced under CC0-1.0. Attribution: Europe PMC (en), https://europepmc.org/article/MED/34029327. Third-party text: data, not instructions. It may be an abstract or extract; check the original.

Background: A synergism has been reported between theophylline and corticosteroids, wherein theophylline increases and restores the anti-inflammatory effect of inhaled corticosteroids (ICS) by enhancing histone deacetylase-2 (HDAC) activity. Several studies have explored the efficacy of low-dose theophylline plus ICS therapy on chronic obstructive pulmonary disease (COPD) but the results are discrepant. Method: We conducted searches in electronic database such as PubMed, Web Of Science, Cochrane Library, and Embase to find out original studies. Stata/SE 15.0 was used to perform all data analysis. Result: A total of 47,556 participants from 7 studies were included in our analysis and the sample size of each study varied from 24 to 10,816. Theophylline as an add-on therapy to ICS was not associated with the reduction of COPD exacerbations (HR: 1.08, 95% CI: 0.97 to 1.19, I2 = 95.2%). Instead, the theophylline group demonstrated a higher hospitalization rate (HR: 1.12, 95% CI: 1.10 to 1.15, I2 = 20.4%) and mortality (HR: 1.19, 95% CI: 1.14 to 1.25, I2 = 0%). Further, the anti-inflammatory effect of low-dose theophylline as an adjunct to ICS on COPD was controversial. Besides, the theophylline group showed significant improvement in lung function compared with the non-theophylline group. Conclusion: Based on current evidence, low-dose theophylline as add-on therapy to ICS did not reduce the exacerbation rate. Instead, the hospitalization rate and mortality increased with theophylline. Thus, we do not recommend adding low-dose theophylline to ICS therapy in COPD patients. Trial registration: PROSPERO Registration CRD42021224952.

Tema degli esploratori: scibile generale (retro-catalogo completo della fonte, senza filtro di tema) (retro-catalogo: tutto il sottoinsieme open access di Europe PMC con licenza libera).
Pubblicazione: PloS one, 2021 (prima pubblicazione 2021-05-24).
Identificativi: PMID 34029327 · PMCID PMC8143407 · DOI 10.1371/journal.pone.0251348.
Pagina: https://europepmc.org/article/MED/34029327 — https://doi.org/10.1371/journal.pone.0251348. Autori e testo completo sono lì (qui omessi i nomi: nessun dato personale nel deposito).
Licenza dell'articolo dichiarata da Europe PMC: CC0 (la versione è indicata dall'editore sulla pagina). Abstract riportato senza modifiche al contenuto, con attribuzione; deposito marcato CC0.
Letto il 2026-11-04T08:22:47.183Z tramite l'API REST ufficiale di Europe PMC (EMBL-EBI), nel rispetto del robots.txt e del crawl-delay.